Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults

P. A. Velasquez-Mieyer, G. E. Umpierrez, R. H. Lustig, A. K. Cashion, P. A. Cowan, Michael Christensen, K. A. Spencer, G. A. Burghen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR®Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct β-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations. DESIGN: Prospective, open-label trial using a pre-post test design. SETTING: Single university, clinical research center. SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93% female, 64% Caucasian, age = 37.8 ± 1.2 y, weight = 123 ± 4.2 kg, BMI = 44.5 ± 1 kg/m2), recruited through physician referral and newspaper ads, participated in the study. INTERVENTIONS: Indices of β-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR. RESULTS: AA exhibited higher β-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.

Original languageEnglish (US)
Pages (from-to)330-333
Number of pages4
JournalInternational Journal of Obesity
Volume28
Issue number2
DOIs
StatePublished - Jan 1 2004

Fingerprint

Glucagon-Like Peptide 1
Octreotide
Somatostatin
Insulin
African Americans
Newspapers
Glucose Tolerance Test
Referral and Consultation
Physicians
Weights and Measures
Research

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Velasquez-Mieyer, P. A., Umpierrez, G. E., Lustig, R. H., Cashion, A. K., Cowan, P. A., Christensen, M., ... Burghen, G. A. (2004). Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. International Journal of Obesity, 28(2), 330-333. https://doi.org/10.1038/sj.ijo.0802561

Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. / Velasquez-Mieyer, P. A.; Umpierrez, G. E.; Lustig, R. H.; Cashion, A. K.; Cowan, P. A.; Christensen, Michael; Spencer, K. A.; Burghen, G. A.

In: International Journal of Obesity, Vol. 28, No. 2, 01.01.2004, p. 330-333.

Research output: Contribution to journalArticle

Velasquez-Mieyer, PA, Umpierrez, GE, Lustig, RH, Cashion, AK, Cowan, PA, Christensen, M, Spencer, KA & Burghen, GA 2004, 'Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults', International Journal of Obesity, vol. 28, no. 2, pp. 330-333. https://doi.org/10.1038/sj.ijo.0802561
Velasquez-Mieyer, P. A. ; Umpierrez, G. E. ; Lustig, R. H. ; Cashion, A. K. ; Cowan, P. A. ; Christensen, Michael ; Spencer, K. A. ; Burghen, G. A. / Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. In: International Journal of Obesity. 2004 ; Vol. 28, No. 2. pp. 330-333.
@article{e545540d2da54c79ba71d248767e736f,
title = "Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults",
abstract = "OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR{\circledR}Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct β-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations. DESIGN: Prospective, open-label trial using a pre-post test design. SETTING: Single university, clinical research center. SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93{\%} female, 64{\%} Caucasian, age = 37.8 ± 1.2 y, weight = 123 ± 4.2 kg, BMI = 44.5 ± 1 kg/m2), recruited through physician referral and newspaper ads, participated in the study. INTERVENTIONS: Indices of β-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR. RESULTS: AA exhibited higher β-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.",
author = "Velasquez-Mieyer, {P. A.} and Umpierrez, {G. E.} and Lustig, {R. H.} and Cashion, {A. K.} and Cowan, {P. A.} and Michael Christensen and Spencer, {K. A.} and Burghen, {G. A.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1038/sj.ijo.0802561",
language = "English (US)",
volume = "28",
pages = "330--333",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults

AU - Velasquez-Mieyer, P. A.

AU - Umpierrez, G. E.

AU - Lustig, R. H.

AU - Cashion, A. K.

AU - Cowan, P. A.

AU - Christensen, Michael

AU - Spencer, K. A.

AU - Burghen, G. A.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR®Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct β-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations. DESIGN: Prospective, open-label trial using a pre-post test design. SETTING: Single university, clinical research center. SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93% female, 64% Caucasian, age = 37.8 ± 1.2 y, weight = 123 ± 4.2 kg, BMI = 44.5 ± 1 kg/m2), recruited through physician referral and newspaper ads, participated in the study. INTERVENTIONS: Indices of β-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR. RESULTS: AA exhibited higher β-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.

AB - OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR®Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct β-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations. DESIGN: Prospective, open-label trial using a pre-post test design. SETTING: Single university, clinical research center. SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93% female, 64% Caucasian, age = 37.8 ± 1.2 y, weight = 123 ± 4.2 kg, BMI = 44.5 ± 1 kg/m2), recruited through physician referral and newspaper ads, participated in the study. INTERVENTIONS: Indices of β-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR. RESULTS: AA exhibited higher β-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.

UR - http://www.scopus.com/inward/record.url?scp=1242284364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242284364&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0802561

DO - 10.1038/sj.ijo.0802561

M3 - Article

VL - 28

SP - 330

EP - 333

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 2

ER -